आईएसएसएन: 2572-4118

स्तन कैंसर: वर्तमान शोध

खुला एक्सेस

हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।

ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं

में अनुक्रमित
  • RefSeek
  • हमदर्द विश्वविद्यालय
  • ईबीएससीओ एज़
  • पबलोन्स
  • आईसीएमजेई
इस पृष्ठ को साझा करें

अमूर्त

Estrogen and BRCA1 Deficiency Work Together to Cause Breast Cancer Mutation-Related DNA Damage

Wenjie Ding

Breast cancer, a complex and heterogeneous disease, is influenced by various genetic, hormonal, and environmental factors. Among these, the interplay between estrogen signaling and the tumor suppressor gene BRCA1 has garnered significant attention due to their individual roles in breast cancer etiology. Estrogen, a pivotal hormone in mammary gland development and function, has been associated with increased breast cancer risk, primarily through its mitogenic and pro-survival effects. On the other hand, BRCA1 plays a critical role in maintaining genomic stability and facilitating DNA repair processes. Mutations in BRCA1 are strongly linked to hereditary breast and ovarian cancers. Recent research suggests a multifaceted interaction between estrogen signaling and BRCA1 function, particularly in the context of DNA damage and repair mechanisms. This review delves into the intricate relationship between estrogen and BRCA1 deficiency, emphasizing their collaborative role in driving breast cancer-associated DNA damage and mutagenesis. We explore the molecular mechanisms through which estrogen can compromise BRCA1-mediated DNA repair, potentially leading to the accumulation of deleterious mutations. Furthermore, we discuss the implications of this synergistic interplay for therapeutic strategies targeting hormone receptor-positive breast cancers with BRCA1 mutations. Enhancing our understanding of how estrogen and BRCA1 deficiency coalesce to promote mutation-related DNA damage is crucial for developing more effective preventive and treatment approaches for breast cancer.